Information  X 
Enter a valid email address

EPIC/TIDM matching '0RQE'

Date
Time Source
Company
Announcement
11 Sep 2019 3:32 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis
03 Sep 2019 4:35 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019
31 Aug 2019 11:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Phase 2 data of aprocitentan, Idorsia’s dual endothelin receptor antagonist, presented at ESC 2019
23 Aug 2019 4:35 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 2019
26 Jul 2019 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis
23 Jul 2019 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Idorsia announces financial results for the first half of 2019
16 Jul 2019 4:35 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Invitation to Idorsia's half year financial results 2019 webcast and conference call
13 Jun 2019 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd (0RQE) Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio
03 May 2019 12:26 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved
18 Apr 2019 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces financial results for the first quarter 2019
29 Mar 2019 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia issues invitation to 2019 Annual General Meeting of Shareholders
07 Feb 2019 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces financial results for 2018 - outstanding progress made - four late stage assets advanced into Phase 3
05 Feb 2019 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
31 Jan 2019 4:35 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Invitation to Idorsia's full year financial results 2018 webcast and conference call
07 Jan 2019 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus
18 Dec 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective
20 Nov 2018 5:00 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone
05 Nov 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia maintains collaboration agreement with ReveraGen
24 Oct 2018 4:36 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Company statement
23 Oct 2018 6:02 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia financial results for the first nine months of 2018
  6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer
24 Jul 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces financial results for the first half 2018
19 Jul 2018 4:35 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Invitation to Idorsia's half year financial results 2018 webcast and conference call
11 Jul 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia successfully completes the offering of new shares and the offering of convertible bonds thereby securing long-term funding for the development of its advancing pipeline
20 Jun 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management
18 Jun 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia is initiating REACT - Phase 3 registration study with clazosentan
11 Jun 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia
16 May 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease
24 Apr 2018 11:45 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia holds its first Annual General Meeting of Shareholders - All Board proposals approved
19 Apr 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces financial results for the first quarter 2018
19 Mar 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia issues invitation to 2018 Annual General Meeting of Shareholders
06 Feb 2018 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces financial results for 2017 - company off to a great start - 4 compounds to enter Phase 3 development
30 Jan 2018 4:40 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Invitation to Idorsia's full year results 2017 webcast and conference call
20 Dec 2017 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia forms research collaboration with Roche in the field of cancer immunotherapy
04 Dec 2017 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces collaboration with Janssen Biotech on aprocitentan (ACT-132577)
24 Oct 2017 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces financial results as of 30 September 2017
16 Oct 2017 4:35 pm GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Invitation to Idorsia's nine-month results 2017 webcast and conference call
03 Aug 2017 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) Idorsia announces half year results for 2017 - successful start of new biopharmaceutical company
28 Jul 2017 6:00 am GNW   Factsheet Idorsia Pharmaceuticals Ltd. (0RQE) ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t